



12<sup>th</sup> November 2025

The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001  
**Scrip Code:** 544250

The Secretary  
National Stock Exchange of India Limited  
C-1, Block G, Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra East, Mumbai - 400 051  
**Symbol:** SANOFICONR

**Sub.: Outcome of Board Meeting held on Wednesday, 12<sup>th</sup> November 2025**

**Dear Sir/Madam,**

We refer to our letter dated 5<sup>th</sup> November 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 12<sup>th</sup> November 2025, *inter-alia* considered and approved the Unaudited Financial Results for the quarter and nine months ended 30<sup>th</sup> September 2025.

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith a copy of the Unaudited Financial Results for the quarter and nine months ended 30<sup>th</sup> September 2025 approved at this Meeting with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company. In this regard, please also find enclosed the accompanying press release.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid Financial Results will also be available on the Company's website on <https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results>

The meeting of Board of Directors commenced at 4:00 p.m. and concluded at 6:00 p.m.

Kindly take the above information on record.

Thanking You,

**Yours faithfully**  
**For Sanofi Consumer Healthcare India Limited**

**Nikunj Kumar Savaliya**  
**Company Secretary and Compliance Officer**  
**Membership No.: F7048**

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

---

## **REVIEW REPORT**

### **TO THE BOARD OF DIRECTORS**

### **SANOFI CONSUMER HEALTHCARE INDIA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sanofi Consumer Healthcare India Limited** ("the Company"), for the quarter and nine months ended September 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), which has been digitally signed by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Company's Board of Directors at their respective meetings held on November 12, 2025, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

### **For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS**

Firm Registration No. 104607W / W100166

### **Sai Venkata Ramana Damarla Partner**

Membership. No. 107017

**UDIN: 25107017BMLFTF2178**

Place: Mumbai

Date: November 12, 2025

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

## Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079

Corporate Identity Number: U21002MH2023PLC402652

Tel no: (91-22) 45288555

Website: www.sanofi.in      Email: igrc.schil@sanofi.com

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025

Particulars	₹ in Million					
	Quarter ended 30.09.2025 (Unaudited)	Quarter ended 30.06.2025 (Unaudited)	Quarter ended 30.09.2024 (Unaudited)	Nine months ended 30.09.2025 (Unaudited)	Nine months ended 30.09.2024 (Unaudited)	Year ended 31.12.2024 (Audited)
1. Revenue from Operations (Refer note 8)	2,339	2,209	1,599	6,274	5,538	7,245
2. Other Income	30	56	42	138	80	130
3. Total Income (1+2)	2,369	2,265	1,641	6,412	5,618	7,375
4. Expenses						
(a) Cost of Materials Consumed	365	554	141	1,108	1,126	1,274
(b) Purchases of stock in trade	260	46	144	641	237	421
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	(7)	12	102	(131)	79	166
(d) Employee benefits expense	317	320	274	933	751	1,027
(e) Finance costs	6	5	34	15	35	39
(f) Depreciation and amortisation expense	33	30	15	83	35	45
(g) Other expenses (Refer note 8)	554	575	307	1,531	1,260	1,651
Total Expenses	1,528	1,542	1,017	4,180	3,523	4,623
5. Profit before exceptional items and tax (3-4)	841	723	624	2,232	2,095	2,752
6. Exceptional items (Refer note 4)	-	66	(12)	66	(255)	(284)
7. Profit before tax (5+6)	841	789	612	2,298	1,840	2,468
8. Tax expense						
Current Tax	225	184	169	579	520	696
Deferred Tax	(13)	(2)	(7)	(17)	(47)	(38)
9. Profit for the period /year (7-8)	629	607	450	1,736	1,367	1,810
10. Other comprehensive income (OCI)						
Items that will not be reclassified to the statement of profit and loss						
- Remeasurements of post-employment benefit obligations	-	-	-	-	-	(19)
- Income Tax impact relating to these items	-	-	-	-	-	5
11. Total comprehensive income for the period/year (9+10)	629	607	450	1,736	1,367	1,796
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	2,500
14. Basic and diluted earnings per share (not annualised) (in ₹)	27.31	26.36	19.52	75.38	59.36	78.59

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations review report dated November 12, 2025.

**Notes:**

1. These unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The Statutory auditors have issued a limited review report with an unmodified conclusion on the above unaudited financial results for the quarter and nine months ended September 30, 2025. The unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 have been reviewed by the Audit Committee in their meeting held on November 12, 2025 and approved by the Board of Directors of the Company at its meeting held on November 12, 2025.
3. The Company had during the previous year voluntarily decided to recall Depura Adult, Depura Kids, Allegra Suspension and Combiflam Suspension from distributors, hospitals, and retailers as a precautionary measure. Subsequently, the Company has successfully relaunched Depura Adult and Combiflam Suspension during the quarter ended March 2025 and June 2025 respectively. Allegra Suspension and Depura Kids were relaunched in quarter ended September 2025. To that effect, the results are not comparable with the corresponding quarters and nine months as the recall had an impact on the domestic business.
4. Exceptional item for nine months ended September 30, 2025 pertains to a reversal of ₹66 million related to demerger provisions made in the previous year. Exceptional item for the nine months ended September 30, 2024, was Rs. 255 million, which included product recall related cost towards Sales return and inventory write off Rs.108 million, expenses towards listing formalities amounting to Rs.77 million and demerger expenses amounting to Rs.70 million. Additionally, year ended December 31, 2024 exceptional item included Intangible asset under development written off amounting to ₹ 29 million (acquired under the Scheme of Arrangement).
5. The Company has a single business segment namely 'Pharmaceutical Business.
6. The Company does not have any subsidiary, associates or joint ventures as on September 30, 2025.
7. On April 30, 2025, Sanofi globally closed the sale to Clayton, Dubilier & Rice Fund XII, L.P. of a 50% controlling stake of Opal JVco S.a.r.l (i.e. Opella group), with Sanofi keeping a significant shareholding of 48.2% stake and Bpifrance owning a 1.8% stake. Consequently, the ultimate Parent of the Company, is now Opal JVco S.a.r.l instead of Sanofi.
8. a) Revenue from operations includes sale of products as under:

Particulars	₹ in Million					
	Quarter ended			Nine months ended		Year ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.12.2024
	(Unaudited)			(Unaudited)		(Audited)
Sales of Product	2,132	1,996	1,477	5,715	5,117	6,689

For the quarter ended September 2025, Domestic sales grew by 20% and Export sales grew by 1031% on a low base, as compared to quarter ended September 2024. For the Nine months ended September 2025, Domestic sales grew by 1% and Export sales grew by 96% on a low base, as compared to Nine months ended September 2024.

b) During the nine month ended September 2024, certain expenses as stated below were shown net of recoveries till the half year ended June 2024. To enhance clarity of financial statements, the expenses and revenue from operations have been regrouped as below. This regrouping does not have any financial impact.

₹ in Million			
Particulars	Nine months ended 30.09.2024		
Results (extract)	Previously reported	Increase	Regrouped
Revenue from Operations	5,355	183	5,538
Other expenses	1,077	183	1,260

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the LODR Regulations review report dated November 12, 2025.

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Himanshu Bakshi  
Managing Director  
DIN: 08188412

November 12, 2025

## Press Release



### Sanofi Consumer Healthcare India Limited reports Q3'25 results

Q3'25 Revenue at ₹2339 million up 46 % Y-O-Y

Q3'25 Net Profit at ₹629 million up 40% Y-O-Y

#### Highlights for the Quarter Y-O-Y:

- Revenue at ₹2339 million, a growth of 46%
- Domestic Sales grew by 20%
- Export Sales grew by more than 10X due to low base
- Profit After Tax was up by 40%

#### Highlights for the Nine Months:

- Revenue at ₹6274 million, a growth of 13%
- Domestic Sales grew by 1%
- Export Sales grew by 96% due to low base
- Profit After Tax was up by 27%

**Mumbai, 12<sup>th</sup> November 2025.** Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) releases its financial results for the third quarter demonstrating growth across key business segments.

Driven by exports and domestic business, revenue growth for the quarter stood at 46% year-on-year for 2025. Profit after tax (PAT) for Q3 reached ₹629 million, a 40% increase over year-on-year basis.

*Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited:*  
"Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer."

**Note:** Quarter and nine months are not directly comparable due to the demerger and voluntary recall of certain variants of key brands in the domestic market.

---

#### About Sanofi Consumer Healthcare India Limited.

Sanofi Consumer Healthcare India Limited (SCHIL) has emerged as a distinct legal entity following its demerger from Sanofi India Limited. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective on 1st June 2024. In alignment with Sanofi's global strategy, SCHIL is now operating independently, with a dedicated focus on the Consumer Healthcare sector.

With an agile business model and strong brands, SCHIL is one of the leading players in India's consumer healthcare market. Leveraging its global experience in consumer healthcare, Sanofi Consumer Healthcare India Limited (SCHIL) aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care and Multivitamins. SCHIL's key brands include Allegra®, DePURA®, Avil® and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.

**Contacts for Media Relations**

Nida Paloba | +91 9821017561 | [nida.paloba@sanofi.com](mailto:nida.paloba@sanofi.com)